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Background/aim: The aim of this study was the determination and prospective follow-up of quality of life, depression, and anxiety in
pediatric patients with cancer under chemotherapy, as well as the evaluation of related factors.
Materials and methods: Fifty newly diagnosed pediatric cancer patients and their parents were prospectively monitored before, during,
and after therapy, and tests were used.
Results: Significantly lower quality of life scores were recorded during treatment, in the group with CNS tumors, in the group receiving
chemotherapy plus radiotherapy plus surgery, in the inpatient-only treatment group, in the group receiving treatment for longer than 6
months, and in the group of patients whose diagnosis was delayed for more than 3 months. Total quality of life scores for children and
their parents were 82.95 ± 14.59 vs. 83.61 ± 14.60 before, 54.69 ± 16.51 vs. 55.78 ± 16.05 during, and 83.88 ± 12.44 vs. 84.19 ± 13.22 at
the end of treatment (P < 0.05). Anxiety and depression scores were significantly higher during treatment, in patients whose diagnoses
were delayed for more than 3 months, and among inpatients.
Conclusion: The quality of life of a majority of our patients was severely affected, and depression and anxiety were more frequently seen
especially during treatment.
Key words: Child, cancer, quality of life, depression, anxiety

1. Introduction
In recent years, assessments of quality of life and the
psychological states of patients have become more
important thanks to the increase in the lifespan of patients
due to intensive and effective treatments applied for
pediatric cancers (1–6).
In addition to disease-related complaints, children
suffering from various types of cancer are exposed to
many traumatic events during diagnostic processes,
including invasive examinations and surgical applications.
After establishment of the diagnosis, prominent physical
adverse effects of chemotherapy and radiotherapy such
as nausea, vomiting, loss of appetite, hair loss, mucositis,
skin problems, pain, weakness, fatigue, symptoms of bone
marrow depression, and infections can be seen. During
treatment, the child is isolated from his/her school,
friends, and family members. All these factors impair the
* Correspondence: demirkayametin@hotmail.com
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quality of life of the children and their families and induce
psychological problems (7–13).
Although it is known that the quality of life of
children with cancer is impaired and the severity of their
anxiety and depression increases, only a small number of
studies prospectively monitored these patients from the
time of diagnosis and investigated fluctuations in their
psychological health state (1–3). In the medical literature,
quality of life, depression, and anxiety have been evaluated
separately, and all these parameters have not been assessed
in combination in the same patient group.
In this study, the aims were the determination and
prospective follow-up of quality of life, depression,
and anxiety in pediatric patients with cancer under
chemotherapy; the comparison of pre-, intra-, and
posttreatment assessments; and an evaluation of related
factors.
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2. Materials and methods
This study was performed in the Division of Pediatric
Oncology of the Faculty of Medicine with newly diagnosed
pediatric cancer patients and their families. Patients
aged 8–18 years who could comprehend the scales and
directives to be used in this study were enrolled. Patients
aged less than 8 and older than 18 years, previously treated
patients still experiencing recurrences, those with motor
or mental dysfunction who could not respond to questions
on the questionnaire forms, patients who were monitored
but did not receive treatment, and patients who could not
complete their treatment were excluded from the study.
A total of 60 children were enrolled in the study. Ten
patients who could not complete the study were excluded,
and the study was finalized with 50 patients. Approval of
the ethics committee was obtained (decree no: 2009 – 9
/ 62). Informed consent forms were obtained from the
patients and their families before their inclusion in the
study.
The patients included in the study were prospectively
monitored before and during the interval between the
2nd and 4th months of chemotherapy and also at least 3
months after therapy using a sociodemographic data form,
the Children’s Depression Inventory (CDI), the Screen for
Child Anxiety Related Emotional Disorders (SCARED) Child Version, and the Pediatric Quality of Life Inventory
(PedsQL) for relevant evaluations. For parents of the
participants, the parents’ version of the Quality of Life
Scale for Children was used.
The same physician conducted the questionnaire
survey, and during the diagnosis, the participants were
examined by a pediatric psychologist and a psychiatrist.
2.1. Questionnaire forms and scales applied
2.1.1. Sociodemographic data form
This form contains questions related to the
sociodemographic data of the patients such as age, sex,
family type, educational levels of the parents, their working
status, monthly income of the family, psychiatric support
(if any), adverse effects of chemotherapy, and information
about their disease such as diagnosis, treatments applied,
and duration of the treatment. This form was filled in by
the researchers based on information gathered from the
patient and his/her medical files.
2.1.2. Pediatric Quality of Life Inventory (PedsQL)
The PedsQL was developed by Varni et al. in 1999 to
measure the health-related quality of life of children and
adolescents aged between 2 and 18 years of age (14).
The PedsQL has questionnaire forms for parents of the
children aged 2–5 years and self-report forms prepared
for pediatric/adolescent patients aged between 5 and 18
years. Although the questionnaire forms prepared for
adolescents and children resemble each other, because of

the differences between cognitive developments of children
and adolescents, simpler words are used for the pediatric
questionnaire. The PedsQL consists of 23 domains. It
inquires about the characteristics of healthiness as defined
by the World Health Organization including physical
health, emotional health, social functioning, and school
functioning. Scoring is performed in three domains as
the total score of the scale (TSS), total physical health
score (PHTS), and total psychosocial health score (TPSS),
including scores evaluating emotional, social, and school
functions items. This scale inquires about the last month
of the children and adolescents, and a Likert-type scale
with 5 alternative responses for each question has been
developed for children and adolescents aged between 8
and 18 years. Items are scored between 0 and 100 points.
The total number of points is divided by the number of
the items completely responded to in order to obtain
the total score. As a consequence, a higher PedsQL total
score signifies a better health-related quality of life. The
validation and reliability of this scale were confirmed for
Turkey (15,16).
2.1.3. Children’s Depression Inventory (CDI)
The CDI contains 27 items aimed at defining the level
of depression in children; a score of 19 points or more is
indicative of depression (17,18).
2.1.4. Screen for Child Anxiety Related Emotional
Disorders (SCARED)
The SCARED test contains 41 Likert-type questions, with
a total score ranging from 0 to 82 points. Higher total
scores indicate higher levels of anxiety (19).
2.2. Statistical analysis
Statistical analysis of data was performed using SPSS
16.0 (SPSS Inc., Chicago, IL, USA). Data were expressed
as means ± standard deviation. With the Kolmogorov–
Smirnov test the assumption of normality could not be
achieved. For time-related variables, percent changes were
calculated. For intergroup comparisons the Kruskal–Wallis
test and/or the Mann–Whitney U test and for intragroup
comparisons the Wilcoxon test were employed.
For the comparison of categorical variables, the
Pearson chi-square test and chi-square test with Yates
correction and for the comparison of ratios the z-ratio
test were used. To analyze relationships among variables,
the Pearson correlation test was performed. P < 0.05 was
accepted as the level of statistical significance.
3. Results
Fifty patients [mean age: 12.14 ± 2.97 years; range: 8–17;
males, n = 30 (60%)] with lymphoma and solid tumors
were included in the study. Diagnosis was made within
3 months [n = 31 (62%)] or more than 3 months [n =
19 (38%)] after the onset of the disease. All patients
received chemotherapy, while some patients received
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radiotherapy (58%) and major surgery (36%). These
treatments consisted of only chemotherapy [n = 13 (26%)],
chemotherapy plus radiotherapy [n = 19 (38%)], surgery
plus chemotherapy plus radiotherapy [n = 10 (20%)], or
surgery plus chemotherapy [n = 8 (16%)] as received by
the indicated number of patients. Patients’ treatment was
continued for less than [n = 24 (48%)] or longer than [n =
26 (52%)] 6 months (Table 1).
Mean quality of life scores calculated before, during,
and after the treatment were 82.95 ± 14.59, 54.69 ± 16.51,
and 83.88 ± 12.44 as assessed by the patients, respectively.
Mean quality of life scores calculated before, during, and
after the treatment were 83.61 ± 14.60, 55.78 ± 16.05,
and 84.19 ± 13.22 as assessed by the parents, respectively.
Scores obtained during treatment were statistically
significantly lower than those calculated before and at the
end of treatment (P < 0.01) (Table 2).
Mean quality of life scores estimated before the
treatment using patients’ and their parents’ PedsQL scales
differed statistically significantly between diagnostic
groups (P < 0.05). In pairwise comparisons, the PedsQL
scores of CNS tumors were significantly lower than those

of the lymphoma patients. When patients’ and their
parents’ PedsQL total and subscale scores were compared,
the lowest scores were estimated for the group receiving
chemotherapy plus radiotherapy plus surgery.
Patients’ and their parents’ PedsQL total and physical
and psychosocial health subscale scores were compared
according to the location of health care services, and in all
assessments, lower scores were obtained in the inpatient
group relative to other groups. Percent changes in the
social functioning subscale scores of the patients estimated
during treatment were statistically significantly lower
relative to pretreatment scores in patients receiving inhospital treatment (P < 0.05). In all assessments, patients’
and their parents’ PedsQL total, physical, and psychosocial
health subscale scores were comparatively lower in the
group under treatment for longer than 6 months. PedsQL
total, physical, and psychosocial health subscale scores of
the patients and their parents were significantly lower in
patients whose diagnoses were delayed for more than 3
months (P < 0.05) (Tables 3 and 4).
In all assessments, mean PedsQL scores of the patients
and their parents were not statistically significantly

Table 1. Characteristics of the patients (n = 50).
Age [years, mean ± SD (range)]

12.14 ± 2.97 (8–17)

Sex [n, (%)]
Female
Male

20 (40)
30 (60)

Diagnosis [n, (%)]
Lymphoma
CNS tumors
Others

24 (48)
7 (14)
19 (38)

Time to diagnosis [n, (%)]
0–3 months
3 months

31 (62)
19 (38)

Treatments [n, (%)]
Chemotherapy
Chemotherapy plus radiotherapy
Chemotherapy plus radiotherapy plus surgery
Chemotherapy plus surgery

13 (26)
19 (38)
10 (20)
8 (16)

Treatment type [n, (%)]		
Outpatient treatment
Inpatient treatment
Outpatient plus inpatient treatment

24 (48)
15 (30)
11 (22)

Duration of treatment [n, (%)]
0–6 months
≥6 months

24 (48)
26 (52)

CNS, Central nervous system; SD, standard deviation.
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Table 2. Quality of life scores.
Pretreatment *

During treatment *

Posttreatment *

Patients’ PedsQL scale
Total score
Physical health score
Psychosocial health score

82.95 ± 14.59
83.34 ± 17.29
83.2 ± 13.92

54.69 ± 16.51
48.51 ± 21.33
59.22 ± 14.61

83.88 ± 12.44
83.47 ± 18.03
84.26 ± 10.58

Parents’ PedsQL scale for children
Total score
Physical health score
Psychosocial health score

83.61± 14.60
84.57 ± 16.94
83.19 ± 14.60

55.78 ± 16.05
48.51 ± 21.33
60.15 ± 14.75

84.19 ± 13.22
83.47 ± 18.03
84.55 ± 11.87

P

a

P

P

b

c

0.001
0.001
0.001

0.992
0.734
0.775

0.001
0.001
0.001

0.001
0.001
0.001

0.907
0.410
0.713

0.001
0.001
0.001

*Mean ± standard deviation; aP, for the comparison of the scores calculated during and before treatment; bP, for the comparison of the
scores obtained before and at the end of treatment; cP, for the comparison of the scores obtained during and at the end of treatment.

different for sex, age of the patients, and educational level
of their parents.
Mean anxiety and depression subscale scores were
compared, and statistically significantly higher scores
were detected during treatment relative to those estimated
before and at the end of treatment (P < 0.01). Based on
depression subscale scores, a significantly higher number
of patients with depressive symptoms was detected during
treatment when compared with before and at the end of
treatment (36%, 18%, and 14%, respectively; P < 0.05)
(Table 5).
Depression subscale scores of the patients were
significantly higher when time to diagnosis was longer than
3 months (P < 0.01). Percent changes in depression scores
calculated during treatment were statistically significantly
different from those estimated before treatment (P < 0.01).
Percent change in depression scores was significantly lower
in patients whose time to diagnosis was longer than 3
months. The patients were compared according to diagnostic
groups and their pretreatment depression scores were not
significantly different. Percent change in depression scores
calculated during treatment was statistically significantly
different relative to pretreatment values (P < 0.05). Based on
the results of pairwise comparisons, percent change in the
depression scores calculated during treatment of lymphoma
patients was significantly higher than that estimated for the
CNS tumor group (P < 0.05). Percent changes calculated
at the end of treatment were not statistically significantly
different between these two groups (Table 6). The rate of
depressive symptoms in inpatients and outpatients or those
receiving treatment on both an inpatient and outpatient
basis were respectively 16.7%, 20%, and 18.2% before
treatment; 37.5%, 53.3%, and 9.1% during treatment; and
8.3%, 26.7%, and 9.1% at the end of the treatment.
Depression subscale scores of the children did not
differ statistically significantly between sex and age groups.
A statistically significant and negative correlation was

detected between depression, anxiety scores, and physical
health scores of the patients and their parents as assessed
during treatment (P < 0.01, r coefficients: –0.693, –0.650,
–0.525, and –0.461, respectively). A statistically significant
and positive correlation was detected between depression
and anxiety scores detected during treatment (P < 0.01, r
= 0.808).
4. Discussion
In this study, when compared with other groups, quality of
life scores were significantly lower during treatment and
in the following groups: the CNS tumor group, the group
receiving chemotherapy plus radiotherapy plus surgery,
the group of patients receiving only inpatient treatment,
the group treated for more than 6 months, and the group
whose diagnosis was delayed for more than 3 months.
Anxiety and depression scores were significantly higher
during treatment in the group of patients whose diagnosis
was delayed for more than 3 months and among inpatients.
Quality of life scores, the presence of depression, and
anxiety did not differ significantly with respect to sex, age,
or the educational level of the parents.
In pediatric patients with cancer, quality of life
decreases due to many factors including surgical
interventions, radiotherapy, chemotherapy, adverse effects
of the treatment, and prolonged hospitalization periods
(20–26). Changes in the quality of life of the patients can
reportedly decrease at 1 month of radiotherapy (14). In
this study, significant decreases in the quality of life scores
were detected during treatment. The lowest score was
recorded in the physical health domain. These outcomes
suggest that during treatment patients are more vulnerable
to the impact of physical factors. Similarly, in many
studies, authors have reported decreases in the quality of
life scores during treatment, mostly in the physical health
scores, and also indicated improvements in these scores
after treatment (2,20).
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Table 3. Comparison of quality of life scores of the patients according to diagnostic groups, treatments applied, type and duration of
treatments, and time to diagnosis. Statistically significant values are shown in bold.
P

P

P

Pretreatment*

During treatment*

Posttreatment*

a

b

Total score
Diagnosis
Lymphomas
CNS tumors
Others

88.27 ± 9.09
71.25 ± 16.68
80.52 ± 16.86

56.89 ± 16.43
63.54 ± 15.14
48.64 ± 15.65

87.38 ± 7.50
79.92 ± 21.24
80.90 ± 12.92

0.049

0.002

0.216

Treatments applied
CT
CT plus RT
CT plus RT plus S
CT plus S

89.26 ± 8.47
84.04 ± 11.66
68.31 ± 20.41
88.40 ± 8.10

51.46 ± 18.05
58.63 ± 14.68
48.47 ± 15.48
58.36 ± 18.84

87.32 ± 7.22
86.43 ± 8.52
74.19 ± 19.94
84.32 ± 11.05

0.062

0.338

0.418

Treatment type
Outpatient treatment
Inpatient treatment
Outpatient plus inpatient

84.64 ± 11.53
80.82 ± 19.09
82.16 ± 14.61

57.65 ± 16.75
48.16 ± 15.72
57.12 ± 15.91

86.80 ± 9.25
79.01 ± 18.41
84.14 ± 5.53

0.216

0.855

0.444

Time to diagnosis
0–3 months
≥ 3 months

88.60 ± 10.96
73.73 ± 15.33

53.94 ± 17.32
55.91 ± 15.48

86.45 ± 8.80
79.67 ± 16.19

0.001

0.011

0.027

Duration of treatment
0–6 months
≥6 months

87.72 ± 10.88
78.53 ± 16.32

56.65 ± 17.31
52.88 ± 15.86

85.57 ± 13.94
82.31 ± 10.91

0.056

0.627

0.089

Physical health score
Diagnosis
Lymphomas
CNS tumors
Others

87.98 ± 11.55
77.22 ± 16.01
79.74 ± 22.39

54.74 ± 18.48
55.77 ± 21.76
37.97 ± 21.34

89.02 ± 9.49
75.87 ± 28.78
79.25 ± 20.30

0.270

0.069

0.372

Treatments applied
CT
CT plus RT
CT plus RT plus S
CT plus S

89.41 ± 10.86
82.02 ± 15.55
71.87 ± 26.19
90.98 ± 7.74

48.04 ± 21.34
52.71 ± 21.95
39.35 ± 19.75
50.76 ± 22.14

89.63 ± 8.68
87.46 ± 11.02
68.09 ± 30.47
83.17 ± 13.78

0.189

0.516

0.281

Treatment type
Outpatient treatment
Inpatient treatment
Outpatient plus inpatient

85.25 ± 12.86
78.94 ± 23.09
85.20 ± 17.23

51.10 ± 23.27
43.10 ± 18.55
50.24 ± 20.97

87.33 ± 11.30
78.09 ± 28.74
82.37 ± 7.93

0.147

0.437

0.644

Time to diagnosis
0–3 months
≥3 months

89.79 ± 13.84
72.82 ± 17.51

47.64 ± 22.57
49.93 ± 19.66

87.98 ± 10.68
76.11 ± 24.56

0.001

0.084

0.004

Duration of treatment
0–6 months
≥6 months

87.07 ± 13.5
79.90 ± 20.10

52.45 ± 21.77
44.90 ± 20.68

85.57 ± 13.94
82.31 ± 10.91

0.255

0.503

0.727

Psychosocial health score
Diagnosis
Lymphomas
CNS tumors
Others

88.72 ± 8.48
67.25 ± 18.17
82.15 ± 13.60

58.86 ± 15.72
69.28 ± 12.39
55.95 ± 12.80

86.68 ± 7.86
82.60 ± 16.28
81.81 ± 11.04

0.018

0.001

0.015
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Table 3. (Continued).
Treatments applied
CT
CT plus RT
CT plus RT plus S
CT plus S

89.57 ± 8.98
85.32 ± 10.07
66.91 ± 17.75
88.30 ± 7.47

54.03 ± 17.43
62.16 ± 12.01
56.91 ± 12.82
63.53 ± 17.02

86.39 ± 7.74
85.90 ± 9.59
77.80 ± 13.95
84.97 ± 10.83

Treatment type
Outpatient treatment
Inpatient treatment
Outpatient plus inpatient

84.96 ± 11.49
82.74 ± 16.30
80.06 ± 15.98

61.46 ± 14.56
53.16 ± 15.10
62.57 ± 12.66

Time to diagnosis
0–3 months
≥3 months

88.43 ± 9.14
74.71 ± 16.27

Duration of treatment
0–6 months
≥6 months

88.36 ± 10.62
78.47 ± 15.07

0.008

0.057

0.128

86.68 ± 9.45
79.75 ± 13.60
85.11 ± 6.20

0.215

0.353

0.305

58.35 ± 15.42
60.63 ± 13.48

85.78 ± 8.78
81.77 ± 12.87

0.003

0.011

0.008

60.25 ± 15.54
58.26 ± 13.95

86.00 ± 11.82
82.65 ± 9.22

0.011

0.286

0.071

*Mean ± standard deviation; CT, chemotherapy; RT, radiotherapy; S, surgery; CNS, central nervous system; aP, for the comparison
of pretreatment values; bP, intergroup comparisons of percent changes calculated during treatment relative to pretreatment values; cP,
intergroup comparisons of percent changes calculated at the end of treatment relative to pretreatment values.

In the literature, lower quality of life scores have been
reported for patients with CNS tumors whose treatment
was completed relative to lymphoma and other cancer
patients (27–32). Eiser et al. (30) reported unfavorable
quality of life scores in adolescent CNS cancer patients
whose treatment was completed when compared with ALL
patients, most prominently observed in the physical and
psychosocial subscale scores. In this study, lower quality of
life scores in patients with CNS were detected, comparable
to the study outcomes reported by Meeske et al. (31) and
Chou et al. (32). This result is associated with the location of
the tumor and neurocognitive changes caused by surgery
and radiotherapy. It reduces the reliability of our results
because CNS tumors existed in only a small proportion of
the patients. Therefore, these results should be confirmed
in larger patient series.
In this study, we have observed that in the patient group
for which all three treatment modalities (chemotherapy
plus radiotherapy plus surgery) were used, quality of life
scores were lower in evaluations. In this group, during
pretreatment evaluations, lower quality of life scores and
statistically significantly decreased psychosocial health
scores were detected. This may be explained by the
evaluation of some patients after application of surgical
treatment, and the awareness of the patients and their
parents about other treatment modalities to be applied.
Psychosocial effects of treatment begin to be influential
long before the initiation of the medical treatment. Lower
quality of life during and after treatment is related to the
increase in side effects seen in parallel with an increase

in treatment modalities. Magal-Vardi et al. (33) found a
correlation between disease severity and quality of life
scores in children with cancer. Landolt et al. (2) reported
that more intensive treatment 6 weeks after diagnosis
and treatment-related complications affected quality of
life. Similar to our study, a higher number of physical
symptoms, greater deterioration of motor functioning, and
marked decrease in emotional functioning were observed
with more intensive treatment. In another study the
stage of the cancer and treatment protocol to be followed
were found to be significantly effective on the quality of
life. Unfavorable effects of additional surgery, intensive
chemotherapy, and hospitalizations on quality of life were
also detected (34).
In some studies, differences between the quality
of life of hospitalized patients and those receiving
ambulatory chemotherapy were reported (35,36). In
this study, though not statistically significant, in patients
receiving therapy while hospitalized lower quality of life
scores were detected when compared with other groups.
Studies performed demonstrated that children receiving
outpatient chemotherapy had higher quality of life scores
relative to inpatients under chemotherapy (37).
In this study, quality of life scores in patients receiving
treatment for longer than 6 months were lower in all
evaluations. Though lower quality of life scores in patients
treated for prolonged periods is to be expected, we
investigated the factors related to the unexpectedly lower
pretreatment scores. When all factors were analyzed,
delays in diagnosis attracted our attention. In 54% of the
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Table 4. Comparison of quality of life scores of the parents’ scale for children according to diagnostic groups, treatments applied, type
and duration of treatments, and time to diagnosis. Statistically significant values are shown in bold.
Pretreatment*

During treatment*

Posttreatment*

Total score
Diagnosis
Lymphomas
CNS tumors
Others

89.10 ± 8.49
71.81 ± 17.81
81.04 ± 16.76

58.37 ± 17.41
64.37 ± 14.87
49.33 ± 12.58

87.19 ± 8.57
79.60 ± 22.20
82.10 ± 13.88

Treatments applied
CT
CT plus RT
CT plus RT plus S
CT plus S

89.73 ± 6.71
84.83 ± 12.56
67.12 ± 18.70
91.40 ± 5.26

54.84 ± 18.57
56.46 ± 14.43
50.19 ± 13.50
62.66 ± 18.44

86.11 ± 7.68
87.64 ± 8.66
74.30 ± 20.47
85.27 ± 14.48

Treatment type
Outpatient treatment
Inpatient treatment
Outpatient + inpatient

86.19 ± 10.89
81.89 ± 18.97
80.34 ± 15.33

58.82 ± 16.31
49.77 ± 14.55
57.32 ± 16.58

88.12 ± 9.17
78.39 ± 18.89
83.54 ± 8.67

Time to diagnosis
0–3 months
≥3 months

89.02 ± 10.01
74.78 ± 16.74

54.48 ± 17.24
57.89 ± 14.06

Duration of treatment
0–6 months
≥6 months

88.87 ± 10.28
78.76 ± 16.42

P

P

P

a

b

0.048

0.003

0.225

0.009

0.466

0.140

0.931

0.467

0.789

86.51 ± 9.95
80.42 ± 16.92

0.001

0.004

0.047

57.57 ± 18.14
54.12 ± 14.00

85.48 ± 13.69
83.01 ± 12.92

0.013

0.554

0.028

89.88 ± 10.40
78.54 ± 16.38
80.07 ± 21.92

54.66 ± 20.31
56.20 ± 23.49
38.77 ± 19.57

88.75 ± 9.17
73.20 ± 29.62
80.88 ± 21.02

0.182

0.886

0.081

Treatments applied
CT
CT plus RT
CT plus RT plus S
CT plus S

91.02 ± 10.56
84.31 ± 16.45
71.54 ± 23.44
90.98 ± 6.98

50.93 ± 20.85
48.81 ± 21.46
39.02 ± 19.70
57.77 ± 24.37

88.90 ± 8.15
88.43 ± 9.99
66.53 ± 30.33
84.73 ± 17.25

0.104

0.944

0.175

Treatment type
Outpatient treatment
Inpatient treatment
Outpatient + inpatient

87.05 ± 12.02
80.97 ± 22.60
84.06 ± 18.02

52.05 ± 23.56
42.49 ± 17.49
50.48 ± 22.11

87.85 ± 10.48
76.82 ± 29.31
83.49 ± 10.08

0.748

0.292

0.583

Diagnosis duration
0–3 months
≥3 months

90.47 ± 11.30
74.93 ± 20.26

46.96 ± 22.12
51.90 ± 2088

88.36 ± 10.99
75.78 ± 24.95

0.002

0.048

0.786

Treatment duration
0–6 months
≥6 months

88.70 ± 11.91
80.75 ± 20.01

52.30 ± 22.22
45.64 ± 20.89

84.97 ± 18.38
82.30 ± 18.80

0.218

0.620

0.198

Psychosocial health scores
Diagnosis
Lymphomas
CNS tumors
Others

88.86 ± 9.15
67.25 ± 19.71
81.91 ± 14.16

60.11 ± 17.51
68.80 ± 12.78
57.01 ± 10.34

86.34 ± 9.84
82.37 ± 18.10
83.10 ± 11.92

0.022

0.001

0.063

Physical health scores
Diagnosis
Lymphomas
CNS tumors
Others

1084

c

SARGIN YILDIRIM et al. / Turk J Med Sci
Table 4. (Continued).
Treatments
CT
CT plus + RT
CT plus RT plus S
CT plus S

89.33 ± 6.51
85.15 ± 11.80
64.40 ± 16.88
92.06 ± 4.52

57.55 ± 18.89
59.87 ± 12.74
57.75 ± 11.51
68.01 ± 15.25

84.57 ± 9.89
87.38 ± 9.63
78.64 ± 15.93
85.20 ± 13.46

Treatment type
Outpatient treatment
Inpatient treatment
Outpatient plus inpatient

85.85 ± 11.48
82.86 ± 17.39
77.85 ± 16.43

62.46 ± 14.54
55.50 ± 15.50
61.43 ± 14.03

88.20 ± 9.70
79.53 ± 14.78
83.45 ± 9.84

Time to diagnosis
0–3 months
≥3 months

88.41 ± 1038
74.68 ± 16.66

58.75 ± 16.21
63.43 ± 12.07

Duration of treatment
0–6 months
≥6 months

89.14 ± 10.52
77.70 ± 15.83

61.05 ± 16.98
59.31 ± 12.65

0.001

0.030

0.025

0.583

0.424

0.259

85.77 ± 10.37
82.57 ± 14.05

0.004

0.004

0.040

85.86 ± 12.11
83.35 ± 11.75

0.005

0.118

0.030

*Mean ± standard deviation; CT, chemotherapy; RT, radiotherapy; S, surgery; CNS, central nervous system; aP, for the comparison
of pretreatment values; bP, intergroup comparisons of percent changes calculated during treatment relative to pretreatment values; cP,
intergroup comparisons of percent changes calculated at the end of treatment relative to pretreatment values.

Table 5. Results of the depression and anxiety scale scores of the patients. Statistically significant values are shown in bold.
Pretreatment*

During treatment*

Posttreatment*

a

P

b

P

Anxiety score

16.68 ± 12.01

25.42 ± 12.37

16.82 ± 8.46

0.001

0.856

0.001

Depression score

8.06 ± 7.35

15.58 ± 7.60

8,82 ± 6.96

0.001

0.444

0.001

c

P

*Mean ± standard deviation; aP, for the comparison of the scores calculated during and before treatment; bP, for the
comparison of the scores obtained before and at the end of treatment; cP, for the comparison of the scores obtained during
and at the end of treatment.

patients receiving treatment for more than 6 months, and
in 21% of those under treatment for 0–6 months, diagnosis
was delayed for more than 3 months. In this study, in
patients whose diagnosis was delayed for more than 3
months, lower quality of life scores were detected. In half
of the patients who were treated for more than 6 months,
we thought that delay in diagnosis for more than 3 months
was associated with lower pretreatment PedsQL scores.
Higher incidence rates of depression were reported in
cancer patients secondary to side effects of chemotherapy
or intractable symptoms of the disease per se. Many
clinicians consider depressive complaints in cancer patients
as normal concomitant symptoms and do not request
psychiatric evaluations. In a study conducted among
cancer patients from 34 centers in England concerning
psychiatric symptoms, a difference of 34.7% was detected

between patients’ and physicians’ quality of life scores.
Based on the outcomes of this study, psychiatric symptoms
of the patients were overlooked and left untreated (38).
In this study, depressive symptoms were detected
before (18%), during (36%), and after (14%) treatment
in the respective percentages of patients. Incidence rates
of depressive disorders were also reported in school-aged
children (2%) and adolescents (15%) (39–41). In pediatric
patients with cancer the incidence of depression and
anxiety ranges between 7% and 53% (33, 42–47).
In this study, the depression and anxiety scores
calculated during treatment were significantly higher than
those detected before and at the end of the treatment.
Higher depression and anxiety scores during treatment
are associated with many factors including tumoral effects,
hospitalization, treatments applied, and their adverse effects.
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Table 6. Intergroup comparisons of depression scales applied for patients. Statistically significant values are shown in bold.
Pretreatment*

During treatment*

Posttreatment*

Depression score
Lymphoma
CNS tumors
Others

5.58 ± 4.29
14.43 ± 8.63
8.84 ± 8.60

15.04 ± 7.78
12.86 ± 5.08
17.26 ± 8.06

7.08 ± 5.03
9.29 ± 10.54
10.84 ± 7.35

Depression score
Time to diagnosis of <3 months
Time to diagnosis of ≥3 months

5.45 ± 4.84
12.32 ± 8.78

15.87 ± 7.90
15.11 ± 7.27

7.87 ± 5.96
10.37 ± 8.28

P

P

P

a

b

c

0.074

0.025

0.373

0.007

0.001

0.090

*Mean ± standard deviation; CNS, central nervous system; aP, for the comparison of pretreatment values; bP, intergroup comparisons of
percent changes calculated during treatment relative to pretreatment values; cP, intergroup comparisons of percent changes calculated at
the end of treatment relative to pretreatment values.

In this study, depression scores were significantly
higher in patients whose diagnosis was delayed for more
than 3 months. Percent changes in scores recorded during
treatment were significantly higher than pretreatment
scores in patients whose diagnosis was established within
3 months after disease onset. These results have revealed
that lower pretreatment depression scores in patients
whose diagnosis was established within a short time
increased during the treatment process, and depression
was observed in a higher percentage of patients while they
were under treatment.
In this study, among groups of patients treated on
an outpatient, inpatient, and both out- and inpatient
basis, comparable percentages of patients had depressive
symptoms before treatment. However, during and at the
end of treatment, a higher percentage of inpatients had
depressive symptoms when compared with the other
groups. Because of the limited sampling size, statistical
comparisons could not be made. However, social
functioning subscale scores were lower in inpatients
during the treatment process. We presumed that
depression scores might be higher in association with these
increased social functioning scores. In many studies, no
marked difference was detected between patients treated
on an outpatient or inpatient basis for the development
of psychological disorders. Though presumably children
treated on an outpatient basis carry lower risk regarding
psychiatric diseases, chemotherapy and radiotherapy exert
many unfavorable adverse effects on the psychological
health state of children. In children receiving outpatient
treatment, stressors such as school absence, separation
from their friends because of risk of infection, and physical
complaints related to the adverse effects of chemotherapy
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(fatigue, weakness, nausea and vomiting, etc.) contribute
to the development of psychological disorders (43,44).
In this study, though not statistically significant,
pretreatment depression scores were higher in the CNS
tumor group. However, during treatment, the percent
change in the depression scores was significantly higher
in the lymphoma group relative to the CNS tumor group.
We think that higher pretreatment depression scores in
the CNS cancer patients might be the reason for detecting
higher depression scores in this group during treatment.
Higher pretreatment depression scores were consistent
with lower quality of life scores.
The strong points of this study include the evaluation of
the patients at the time of diagnosis and, with prospective
monitorization, reevaluation of the patients during and
after treatment so as to compare quality of life scale scores.
Quality of life, depression, and anxiety were evaluated in
combination and related factors were analyzed. Among its
limitations, the small number of patients, lack of a control
group, and determination of the lowest age limit of the
patients as 8 years of age can be mentioned.
In conclusion, this study was conducted mostly in the
pediatric age group among patients who received intensive
therapy, and the patients were prospectively followed. In
the majority of the patients, especially during treatment,
quality of life was seriously affected and depression and
anxiety were encountered at an increased incidence.
Although improvement in these rates was observed after
treatment, these patients should be followed for a longterm period as regards quality of life, depression, and
anxiety. As far as we know, no other study has evaluated
quality of life, depression, and anxiety in combination and
followed them prospectively in the same patient group.
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